Parent Questionnaire Shows Strong Promise for Spotting Cognitive Problems in Childhood Cancer Survivors

Every year, thousands of children survive cancer, but for many of them the battle does not end when the tumors disappear. Chemotherapy, cranial radiation, and the biological stress of malignancy itself can leave lasting scars on the developing brain, quietly eroding memory, attention, processing speed, and the executive functions that govern planning and self-control. These neurocognitive late effects can shape a survivor’s entire life trajectory, influencing school performance, friendships, employment, and long-term financial independence. Yet identifying which children need specialized neuropsychological evaluation has long depended on the judgment of busy oncology providers, whose training in cognitive assessment varies widely. A new study published in the Journal of Cancer Survivorship offers a strikingly practical answer: a structured parent-report questionnaire that appears to capture, with remarkable statistical strength, the same clinical instincts that experienced specialists apply at the bedside.

The tool, known as the CNC3 Caregiver Report Questionnaire or CNC3-CRQ, was developed by the Clinical Neuropsychology Collaborative for Childhood Cancers, a multi-institutional group of board-certified neuropsychologists working at leading pediatric cancer centers across North America. Their goal was deceptively simple: to give survivorship clinics a standardized, caregiver-driven screening instrument that could flag children who should be referred for formal neuropsychological services. In the new study, researchers led by Rachel S. Werk of Ann and Robert H. Lurie Children’s Hospital of Chicago and Northwestern University Feinberg School of Medicine put the questionnaire to the test in a real-world clinical setting, comparing its results directly against the referral recommendations made by the survivorship providers who cared for the children.

The study enrolled 173 childhood cancer survivors seen at a pediatric oncology survivorship clinic, a population that reflected the typical composition of long-term follow-up programs. Roughly 41 percent of the participants had a history of hematologic malignancy, such as leukemia or lymphoma, while 20 percent had survived a central nervous system tumor, the group at highest known risk for cognitive impairment. Parents completed the CNC3-CRQ, answering items that probe multiple neurocognitive domains, and the questionnaire generated both a cumulative screening result and domain-specific scores. Positive scores on the instrument were designed to indicate a need for referral to neuropsychology. Independently, and without knowledge of the questionnaire results, each child’s survivorship provider made a clinical recommendation about whether neuropsychological referral was warranted, creating a natural head-to-head comparison between structured screening and clinical gestalt.

The headline finding was the sheer scale of need the questionnaire uncovered. The CNC3-CRQ recommended neuropsychological referral for 68.2 percent of the survivors screened, a figure that underscores just how common cognitive concerns are in this population and how much unmet demand may be hiding beneath the surface of routine follow-up care. Prior research has documented that even survivors treated with chemotherapy alone, without any radiation to the brain, can show measurable deficits in attention, executive function, and processing speed years after treatment ends. Systematic reviews and meta-analyses have linked these deficits to lower educational attainment, reduced employment, and financial hardship in adulthood, making early identification not merely a clinical nicety but a matter of lifelong equity and opportunity.

Statistically, the convergence between the questionnaire and the clinicians was compelling. Survivors whose providers recommended neuropsychological referral had dramatically higher odds of a positive cumulative screen on the CNC3-CRQ, with an odds ratio of 13.2 and a 95 percent confidence interval spanning 3.76 to 52.1, a result significant at p less than 0.001. In plain terms, when an experienced oncology provider felt a child needed neuropsychological evaluation, the parent questionnaire very often agreed. The relationship held across every neurocognitive domain the instrument measures: parental level of concern and the percentage of symptoms endorsed were significantly and positively associated with provider recommendations in each domain. This domain-by-domain agreement matters because neuropsychological referral decisions are rarely about a single global score; clinicians weigh specific patterns, such as whether a child struggles primarily with working memory, language, or behavioral regulation.

One of the study’s most revealing analyses examined what actually drove providers’ referral decisions. When the researchers asked providers to state their specific reasons for recommending neuropsychology, reported parent or caregiver concern emerged as a key factor, and it was significantly associated with a positive score in the questionnaire’s Executive Functions: Behavior domain, with an odds ratio of 2.45, a 95 percent confidence interval of 1.06 to 5.95, and p less than 0.05. This finding highlights a subtle but important truth about pediatric survivorship care: parents are often the first to notice that something has changed in their child’s ability to organize homework, control impulses, or navigate social situations. A well-designed caregiver-report instrument effectively formalizes and quantifies that parental radar, converting it into data that can trigger timely evaluation rather than waiting for problems to escalate.

The convergence observed in this study is what psychometricians call convergent validity, the degree to which a new instrument agrees with an established criterion. Here the criterion was the accumulated clinical judgment of oncology providers who specialize in the care of childhood cancer survivors, providers who see the late effects of therapy every day. Achieving an odds ratio above 13 for the cumulative screen suggests the questionnaire is not merely duplicating generic developmental checklists but is genuinely tuned to the neurocognitive signature of pediatric cancer treatment. The instrument’s lineage reflects this specificity: it builds on earlier work by Jin-Shei Lai and colleagues, who developed parent-report cognitive function item banks using item response theory and explored their utility in computerized adaptive testing, a modern psychometric approach that allows brief assessments to remain precise across a wide range of ability levels.

Why does a screening tool like this matter so much? Comprehensive neuropsychological assessment is the gold standard for characterizing cognitive late effects, but it is a scarce resource. Board-certified pediatric neuropsychologists are concentrated in major academic centers, and studies have documented demographic, medical, and neighborhood barriers that prevent many children, particularly those from underserved communities, from ever reaching these services. Professional guidelines, including the Children’s Oncology Group’s long-term follow-up guidelines and standards of care articulated in pediatric oncology literature, call for monitoring of neuropsychological outcomes, yet surveys show that delivery of psychosocial and cognitive screening remains inconsistent across institutions. A brief parent-report questionnaire requires no specialized equipment, no dedicated testing sessions, and no neuropsychologist to administer, which means it can be embedded into routine survivorship visits even at community-based clinics far from academic hubs.

The study’s authors are careful about what the tool is and is not. The CNC3-CRQ is a screening and decision-support instrument, not a diagnostic test; a positive screen signals the need for comprehensive evaluation, it does not itself establish impairment. And because the comparison criterion was provider recommendation rather than formal neuropsychological testing, the study cannot yet say how the questionnaire performs against full assessment batteries. The researchers also note that the tool may be particularly valuable for providers with less experience identifying neurocognitive late effects, which is precisely the gap that exists in many treatment centers. In this sense, the questionnaire functions less as a replacement for clinical expertise and more as a democratizing force, packaging the pattern-recognition of specialist centers into a form any survivorship program can deploy.

The implications reach well beyond a single clinic. If validated in broader and more diverse populations, caregiver-report screening could become a standard element of long-term follow-up, ensuring that children treated for leukemia in a community hospital receive the same cognitive surveillance as those treated at a comprehensive cancer center. It could also help standardize research, giving multi-site studies a common metric for identifying survivors at risk and measuring the benefits of cognitive rehabilitation interventions. For the families of the roughly 68 percent of survivors the questionnaire flagged in this cohort, the message is equally direct: the concerns they carry home from clinic visits are real, measurable, and now, increasingly, something the health system can act upon systematically. As survival rates for childhood cancer continue to climb past 85 percent, the frontier of pediatric oncology is shifting from curing the disease to protecting the decades of life that follow, and tools like the CNC3-CRQ represent an elegant, low-cost step in that direction.

Subject of Research: Validation of a caregiver-report neuropsychological screening tool for identifying childhood cancer survivors needing neuropsychology referral

Article Title: A comparison of a novel neuropsychological screening tool with provider recommendations among pediatric cancer survivors

Article References: Werk, R. S., Haldipurkar, S. K., Reichek, J. L., Waanders, A. J., Paek, S., Baptiste, S., Lai, J.-S., & Powell, S. K. (2026). A comparison of a novel neuropsychological screening tool with provider recommendations among pediatric cancer survivors. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-026-02136-9

Image Credits: AI Generated

DOI: 10.1007/s11764-026-02136-9

Keywords: childhood cancer survivors, neuropsychological screening, CNC3-CRQ, neurocognitive late effects, cancer survivorship, caregiver report, executive function, pediatric oncology, convergent validity, referral decision support, cognitive impairment, Journal of Cancer Survivorship